Abstract
Cell-fate control gene therapy (CFCGT)-based strategies can augment existing gene therapy and cell transplantation approaches by providing a safety element in the event of deleterious outcomes. Previously, we described a novel enzyme/prodrug combination for CFCGT. Here, we present results employing novel lentiviral constructs harboring sequences for truncated surface molecules (CD19 or low-affinity nerve growth factor receptor) directly fused to that CFCGT cDNA (TmpkF105Y). This confers an enforced one-to-one correlation between cell marking and eradication functions. In-vitro analysis demonstrated the full functionality of the fusion product. Next, low-dose 3′-azido-3′-deoxythymidine (AZT) administration to non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice injected with transduced clonal K562 cells suppressed tumor growth; furthermore, one integrated vector on average was sufficient to mediate cytotoxicity. Further, in a murine xenogeneic leukemia-lymphoma model we also demonstrated in-vivo control over transduced Raji cells. Finally, in a proof-of-principle study to examine the utility of this cassette in combination with a therapeutic cDNA, we integrated this novel CFCGT fusion construct into a lentivector designed for treatment of Fabry disease. Transduction with this vector restored enzyme activity in Fabry cells and retained AZT sensitivity. In addition, human Fabry patient CD34+ cells showed high transduction efficiencies and retained normal colony-generating capacity when compared with the non-transduced controls. These collective results demonstrated that this novel and broadly applicable fusion system may enhance general safety in gene- and cell-based therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA . Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18: 843–851.
Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M . Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010; 18: 666–668.
Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719–1724.
Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 2001; 97: 63–72.
Berger C, Flowers ME, Warren EH, Riddell SR . Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006; 107: 2294–2302.
Garin MI, Garrett E, Tiberghien P, Apperley JF, Chalmers D, Melo JV et al. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 2001; 97: 122–129.
Deschamps M, Mercier-Lethondal P, Certoux JM, Henry C, Lioure B, Pagneux C et al. Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft. Blood 2007; 110: 3842–3852.
Blumenthal M, Skelton D, Pepper KA, Jahn T, Methangkool E, Kohn DB . Effective suicide gene therapy for leukemia in a model of insertional oncogenesis in mice. Mol Ther 2007; 15: 183–192.
Willmon CL, Krabbenhoft E, Black ME . A guanylate kinase/HSV-1 thymidine kinase fusion protein enhances prodrug-mediated cell killing. Gene Therapy 2006; 13: 1309–1312.
Black ME, Kokoris MS, Sabo P . Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res 2001; 61: 3022–3026.
Ardiani A, Sanchez-Bonilla M, Black ME . Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo. Cancer Gene Ther 2010; 17: 86–96.
Akyurek LM, Nallamshetty S, Aoki K, San H, Yang ZY, Nabel GJ et al. Coexpression of guanylate kinase with thymidine kinase enhances prodrug cell killing in vitro and suppresses vascular smooth muscle cell proliferation in vivo. Mol Ther 2001; 3: 779–786.
Stasi AD, Tey SK, Fujita Y, Cruz R, Martinez C, Kennedy-Nasser A et al. CASPALLO: phase I clinical trial of allodepleted T cells transduced with inducible caspase 9 suicide gene after haploidentical stem cell transplantation. Mol Ther 2010; 18: S110.
Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK . Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 913–924.
Sato T, Neschadim A, Konrad M, Fowler DH, Lavie A, Medin JA . Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther 2007; 15: 962–970.
Brundiers R, Lavie A, Veit T, Reinstein J, Schlichting I, Ostermann N et al. Modifying human thymidylate kinase to potentiate azidothymidine activation. J Biol Chem 1999; 274: 35289–35292.
Ostermann N, Lavie A, Padiyar S, Brundiers R, Veit T, Reinstein J et al. Potentiating AZT activation: structures of wild-type and mutant human thymidylate kinase suggest reasons for the mutants’ improved kinetics with the HIV prodrug metabolite AZTMP. J Mol Biol 2000; 304: 43–53.
Ramsubir S, Yoshimitsu M, Medin JA . Anti-CD25 targeted killing of bicistronically transduced cells: a novel safety mechanism against retroviral genotoxicity. Mol Ther 2007; 15: 1174–1181.
Yoshimitsu M, Higuchi K, Ramsubir S, Nonaka T, Rasaiah VI, Siatskas C et al. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Gene Therapy 2007; 14: 256–265.
Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415–419.
Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118: 3132–3142.
GlaxoSmithKline. (2010). Full Prescribing Information Package Insert for Retrovir.
Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 1996; 88: 1188–1197.
Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res 2000; 6: 1302–1313.
Omar RF, Gourde P, Desormeaux A, Tremblay M, Beauchamp D, Bergeron MG . In vivo toxicity of foscarnet and zidovudine given alone or in combination. Toxicol Appl Pharmacol 1996; 139: 324–332.
Tan X, Boudinot FD, Chu CK, Egron D, Perigaud C, Gosselin G et al. Pharmacokinetics of bis(t-butyl-SATE)-AZTMP, a bispivaloylthioethyl prodrug for intracellular delivery of zidovudine monophosphate, in mice. Antivir Chem Chemother 2000; 11: 203–211.
Quevedo MA, Brinon MC . In vitro and in vivo pharmacokinetic characterization of two novel prodrugs of zidovudine. Antiviral Res 2009; 83: 103–111.
Wannachaiyasit S, Chanvorachote P, Nimmannit U . A novel anti-HIV dextrin-zidovudine conjugate improving the pharmacokinetics of zidovudine in rats. AAPS PharmSciTech 2008; 9: 840–850.
Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G et al. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. Clin Cancer Res 2008; 14: 569–578.
Bilello JA, Eiseman JL, Standiford HC, Drusano GL . Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy. Antimicrob Agents Chemother 1994; 38: 628–631.
Kase R, Shimmoto M, Itoh K, Utsumi K, Kotani M, Taya C et al. Immunohistochemical characterization of transgenic mice highly expressing human lysosomal alpha-galactosidase. Biochim Biophys Acta 1998; 1406: 260–266.
Zarate YA, Hopkin RJ . Fabry's disease. Lancet 2008; 372: 1427–1435.
Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V et al. The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells. Sci Transl Med 2011; 3: 111–120.
Medin JA, Tudor M, Simovitch R, Quirk JM, Jacobson S, Murray GJ et al. Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc Natl Acad Sci USA 1996; 93: 7917–7922.
Walia JS, Neschadim A, Lopez-Perez O, Alayoubi A, Fan X, Carpentier S et al. Autologous transplantation of lentivector/acid ceramidase-transduced hematopoietic cells in non-human primates. Hum Gene Ther 2011; 22: 679–687.
Qin G, Takenaka T, Telsch K, Kelley L, Howard T, Levade T et al. Preselective gene therapy for Fabry disease. Proc Natl Acad Sci USA 2001; 98: 3428–3433.
Acknowledgements
We would like to especially thank the Fabry patients who donated bone marrow to facilitate these studies. This research was funded by a research operating grant from the Canadian Institutes of Health Research to Dr JA Medin. Funding for AN was provided by the CIHR Training Program in Regenerative Medicine (TPRM).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Scaife, M., Pacienza, N., Au, B. et al. Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes. Gene Ther 20, 24–34 (2013). https://doi.org/10.1038/gt.2011.210
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2011.210
Keywords
This article is cited by
-
Sarcoma IL-12 overexpression facilitates NK cell immunomodulation
Scientific Reports (2021)
-
Essential thrombocytosis attributed to JAK2-T875N germline mutation
International Journal of Hematology (2019)
-
Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML
Molecular Therapy - Methods & Clinical Development (2016)
-
Gene Therapy for Fabry Disease: A Review of the Literature
BioDrugs (2013)